Intelligence Β· Clinical Pipeline
Phase I Pipeline Programs
First-in-human and early clinical safety studies in Phase I.
- Programs
- 4,713
Quick answer
NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.
Top sponsors
- BRIGHT MINDS BIOSCIENCES 327 programs
- Takeda 276 programs
- Anaxis Pharma 204 programs
- Chinese Academy of 190 programs
- United Therapeutics Europe 184 programs
- Teva Pharma 154 programs
- First People's Hospital 149 programs
- Regeneron UK 126 programs
- Boehringer Ingelheim 94 programs
- Sunshine Guojian Pharmaceutical 85 programs
- Lakefront Biotherapeutics NV 62 programs
- HOFFMANN-LA ROCHE 58 programs
-
MK-4646 Single Ascending Dose Study and DDI in Healthy Participants
Merck Sharp and Dohme
HIV infection
1 trial -
MK-7091 Formulations Study in Healthy Adult Participants
Merck Sharp and Dohme
Hypercholesterolemia
1 trial -
MK-7480 Multiple Ascending Dose Study in Healthy Participants
Merck Sharp and Dohme
Non-alcoholic steatohepatitis
1 trial -
MKC-1
CASI Pharmaceuticals
Hematological Malignancies
1 trial -
MLN0128
Takeda
Advanced Solid Malignancies
2 trials -
MLN0264
Takeda
Advanced Gastrointestinal Carcinoma
1 trial -
MLN0264
Takeda
Advanced Gastrointestinal Malignancies
1 trial -
MLN1117
Takeda
Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
1 trial -
MLN1202
Takeda
Healthy Japanese and Caucasian Male Adults
1 trial -
MLN2480
Takeda
Melanoma
1 trial -
MLN2480
Takeda
Advanced Nonhematologic Malignancies
1 trial -
MLN3126
Takeda
Safety
1 trial -
MLN3126
Takeda
Healthy Volunteers
1 trial -
MLN4924
Takeda
Solid Tumors
1 trial -
MLN4924
Takeda
Advanced Solid Tumors
1 trial -
MLN4924
Takeda
Acute Myelogenous Leukemia
1 trial -
MLN7243
Takeda
Advanced Malignant Solid Tumors
1 trial -
MMV390048 40 mg
CNS Pharmaceuticals
Malaria
1 trial -
MNPR-101-DFO*-89Zr
Monopar Therapeutics
Solid Tumor, Adult
1 trial -
MNPR-101-PCTA-177Lu
Monopar Therapeutics
Solid Tumor, Adult
1 trial -
MOR106
Lakefront Biotherapeutics NV
Healthy
1 trial -
MOR106 single ascending doses, intravenous
Lakefront Biotherapeutics NV
Healthy
1 trial -
MP-424 (Telaprevir)
Vertex Pharmaceuticals (Australia) Pty.
Chronic Hepatitis C
1 trial -
MP-424(H), PEG-IFN-a-2b, RBV
Vertex Pharmaceuticals (Australia) Pty.
Hepatitis C
1 trial -
MPT0B640
INTENSITY THERAPEUTICS, INC.
Advanced Solid Tumor
1 trial -
MPT0B640
INTENSITY THERAPEUTICS, INC.
Covid19
1 trial -
MRG007
ArriVent BioPharma
Locally Advanced or Metastatic Solid Tumors
1 trial -
MRT-6160
Monte Rosa Therapeutics
Healthy Volunteers
1 trial -
MRT-8102
Monte Rosa Therapeutics
Healthy Volunteers
1 trial -
MRx-4DP0004
4D Molecular Therapeutics
Asthma
1 trial -
MRx0029
4D Molecular Therapeutics
Idiopathic Parkinson Disease
1 trial -
MRx0518
4D Molecular Therapeutics
Pancreatic Cancer
1 trial -
MRx0518 Capsules
4D Molecular Therapeutics
Melanoma
1 trial -
MSB11455
Fresenius Kabi Australia Pty Limited
Healthy
1 trial -
MSB11456
Fresenius Kabi Australia Pty Limited
Healthy
1 trial -
MSC-derived exosomes
Regeneron Ireland Designated Activity Company (DAC)
Long COVID-19 Syndrome
1 trial -
MSC2156119J
Merck KGaA, Darmstadt, Germany
Solid Tumors
1 trial -
MSCs
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19
1 trial -
MSCs-derived exosomes
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronavirus
1 trial -
MSD-001
Lxo Ireland Designated Activity Company
Mental Health Disorders
1 trial -
MT-1186
Tanabe Pharma
Healthy Adult Subjects
1 trial -
MT-401-OTS
Marker Therapeutics
Acute Myeloid Leukemia, in Relapse
1 trial -
MT-601
Marker Therapeutics
Non-Hodgkin Lymphoma, Adult
1 trial -
MT-601 dose 200 million cells
Marker Therapeutics
Pancreas Cancer
1 trial -
MT203 80 mg or matching Placebo
Takeda
Healthy Volunteers
1 trial -
MTL-CEBPA
Hospital Authority, Hong Kong
Advanced Hepatocellular Carcinoma
1 trial -
MTX110
Biodexa Pharmaceuticals Plc
Recurrent Glioblastoma
1 trial -
MUNC13.4-CD34 suspension, MUNC13.4-T3 suspension
Pari Pharma GmbH
Familial Hemophagocytic Lymphohistiocytosis (FHL)
1 trial
Frequently asked questions
How many Phase I pipeline programs are in the directory?
4,713 published programs match this development stage in our ClinicalTrials.gov index.
What defines this pipeline stage?
Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.
Data attribution: Data sources Β· All pipeline programs